Unternehmensübersicht
Senti Biosciences, Inc. operates as a clinical stage biotechnology firm dedicated to the development of cell and gene therapies that leverage proprietary gene circuit platform technologies for patients suffering from incurable diseases. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it focuses on advancing off-the-shelf healthy adult donor derived natural killer (NK) cell product candidates. According to available financial data, the company holds a market capitalization of $26.54M and reports an annual revenue of $22,000 over the trailing twelve months. With an employee count listed as N/A, the firm currently operates on a micro-cap scale characterized by very limited revenue generation relative to its valuation. This market cap figure of $26.54M combined with minimal revenue indicates that the company is in an early-stage development phase where valuation is driven primarily by potential future pipeline value rather than current earnings or sales volume. The disparity between the substantial market cap and the negligible revenue of $22,000 underscores the speculative nature of biotechnology investments at this stage, where investor capital is allocated based on the potential of the lead product candidates rather than established commercial performance.
Finanzielle Gesundheit
The financial statements for Senti Biosciences, Inc. reveal a revenue of $22,000 over the trailing twelve months, accompanied by a net income of $-61,438,000 and an EBITDA of $-54,667,000. The significant gap between the minimal revenue of $22,000 and the substantial net loss of $-61,438,000 highlights a cost structure dominated by high research and development expenses typical of clinical stage biotechnology companies. Free cash flow stands at $-23,338,000, indicating that the company is burning cash rapidly to fund its operations and clinical trials, which severely limits its immediate financial flexibility without external capital raises. Three distinct margin metrics further illustrate the company's financial position: a gross margin of 0.0%, an operating margin of -37095.5%, and a profit margin of 0.0%. The negative operating margin of -37095.5% specifically reflects the massive overhead costs incurred relative to the tiny sales base, while the 0.0% gross and profit margins confirm that the company has not yet achieved profitability or cost recovery on its products. On the balance sheet, the company holds $16.73M in cash against total debt obligations of $28.89M, resulting in a debt-to-equity ratio of 516.93. This leverage ratio combined with debt exceeding cash reserves suggests a highly leveraged balance sheet that relies heavily on future financing events to meet obligations. Liquidity is supported by a current ratio of 1.67, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, though this buffer must be weighed against the aggressive debt load. Return on Equity is reported at -218.1% and Return on Assets at -48.9%, metrics that reveal management is currently unable to generate positive returns on shareholder capital or the asset base due to the heavy investment phase and accumulated losses.
Bewertungsanalyse
Valuation multiples for Senti Biosciences, Inc. reflect its lack of profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.95. The forward P/E of -0.95, derived from negative earnings, implies that the market is pricing the stock based on future expectations rather than current performance, while the absence of a trailing P/E confirms that historical earnings are negative. The price-to-book ratio stands at 4.71, indicating that the market values the company at a significant premium over its book value, a common characteristic for biotech firms with intangible assets and development potential. Alternative valuation metrics show a price-to-sales ratio of 1206.28 and an EV/EBITDA of -0.71, suggesting that the stock is priced almost entirely on the theoretical future success of its pipeline rather than any current revenue generation or earnings power. The stock has exhibited high volatility within its trading range, with a 52-week high of $5.10 and a 52-week low of $0.77. Given the current market cap of $26.54M and the wide spread between these price points, the share price sits within a range that reflects significant investor uncertainty and sentiment swings typical of speculative small-cap biotechnology stocks. The beta value of 2.12 indicates that the stock's price volatility is more than double that of the broader market, meaning it is highly sensitive to sector-specific news and general market fluctuations.
Growth & Income
Growth metrics for Senti Biosciences, Inc. are currently unavailable, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A due to the lack of sufficient historical financial data to calculate year-over-year changes. In the absence of measurable growth rates or a history of profitability, the concept of earnings growing faster or slower than revenue is not applicable in the traditional sense for a company reporting such minimal revenue figures. As a non-dividend payer, the company does not distribute dividends to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This 0.0% payout ratio is consistent with the company's strategy of retaining all available resources to fund clinical development and operational expenses rather than paying out income to investors. The overall growth and income profile is defined by a complete reliance on capital markets for funding, as the company reinvests its minimal cash reserves and potentially new equity issuances into its gene circuit platform technologies rather than generating cash flow or income distributions.